Placulumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | TNF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C3404H5262N902O1036S22 |
| Molar mass | 76104.14 g·mol−1 |
Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1]
This drug was developed by Teva Pharmaceutical Industries, Inc. As of 2012, development of placulumab has been discontinued.[2]
References
[edit]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Placulumab, American Medical Association.
- ^ Antoniu SA (November 2013). "Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012)". Expert Opinion on Investigational Drugs. 22 (11): 1453–64. doi:10.1517/13543784.2013.836489. PMID 24024675.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |